The short version of chelation fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
The molecular weight and charge of GHK-Cu depend on the pH and the number of coordinated ligands. At neutral pH, the peptide typically binds one copper ion, but ternary complexes with other biomolecules can form. Spectroscopic methods such as electron paramagnetic resonance and circular dichroism are used to study the coordination environment. Reports on the exact geometry vary because the complex is dynamic in solution. Researchers often use synthetic GHK-Cu rather than extracted material to control stoichiometry and purity.
GHK-Cu is a coordination complex formed from the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, the terminal amino group, and the deprotonated amide nitrogen. This arrangement creates a square-planar or distorted geometry around the metal center, depending on pH and the presence of competing ligands. The complex occurs naturally in human plasma, saliva, and urine at low concentrations, and its sequence is conserved across many vertebrate species.
Discovery of GHK is generally attributed to work in the 1970s that isolated a plasma factor influencing liver cell behavior. Subsequent studies identified the copper-binding tripeptide and its ability to chelate copper with high affinity. Early reports linked the complex to wound healing and tissue remodeling in animal models. The free peptide and the copper-bound form have different properties, so the two are distinguished in the literature. Whether endogenous GHK-Cu serves a single primary physiological role remains an open question.
Identity and purity are established with a combination of chromatographic and spectroscopic techniques. Reversed-phase high-performance liquid chromatography separates the intact complex from peptide fragments and free copper, and the elution profile yields a purity estimate. Mass spectrometry gives the mass of the intact species and exposes degradation products. Ultraviolet-visible spectroscopy displays a broad absorption band in the visible region that is characteristic of the copper center. Nuclear magnetic resonance is less informative here, because the paramagnetic metal broadens signals and complicates spectral interpretation.
Copper content is measured separately, since a peptide assay alone does not report the metal-to-peptide ratio. Elemental techniques such as inductively coupled plasma optical emission spectroscopy quantify copper after acid digestion of the sample. The result is compared with the theoretical value for a one-to-one complex, and a shortfall indicates free peptide or partial dissociation. Suppliers differ in how they state purity, as some quote peptide content and others quote the whole complex. A defined stoichiometry therefore requires both a peptide assay and a copper assay.
Solid GHK-Cu is usually supplied as a lyophilized powder and is kept cold and dry. Moisture, light, and repeated temperature cycling shorten its useful life in the laboratory. In aqueous solution the complex undergoes slow hydrolysis of the peptide backbone and gradual loss of coordinated copper. Buffers containing strong chelators, such as EDTA, compete for the metal and strip it from the peptide. Working solutions are therefore prepared shortly before use, and leftover liquid is not returned to the stock container.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Gly-His-Lys | Tripeptide; copper binds via His and N-terminus |
| Copper stoichiometry | Typically 1 Cu(II) per peptide | Can form ternary complexes under some conditions |
| Molecular formula (peptide) | C14H24N6O4 | Free peptide; copper complex mass differs |
| Appearance (solid) | Blue to blue-green powder | Color derives from copper d-d transitions |
| Solubility | Soluble in water and polar solvents | Solubility depends on pH and counterions |
Quality control for GHK-Cu relies on documentation and independent testing rather than a single accepted standard. A certificate of analysis may report peptide purity, copper content, residual solvents, water content, and microbial limits, but the underlying methods and acceptance criteria vary by supplier. Verification can include mass confirmation, amino acid analysis, and comparison with a reference standard when one is available. Open questions include how different copper-binding modes or peptide isomers affect measured activity and whether conventional purity assays capture those differences. Buyers of research-grade material typically need to request raw data rather than rely solely on a summary certificate.
Laboratory characterization of GHK-Cu typically combines separation, spectroscopic, and elemental techniques. Reverse-phase high-performance liquid chromatography is widely used to assess peptide purity, often with ultraviolet detection near the copper-related absorption band or with mass spectrometry for identity confirmation. Because the molecule contains copper, elemental methods such as inductively coupled plasma mass spectrometry or atomic absorption spectroscopy are used to quantify metal content and confirm stoichiometry. No single universal pharmacopeial monograph exists for GHK-Cu. Laboratories therefore validate their own methods, and reported purity values depend on the chosen assay and calibration standards.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
Purity assessment typically involves high-performance liquid chromatography for the peptide and atomic spectroscopy for copper content. The ratio of copper to peptide is a key quality parameter; a value near one indicates proper stoichiometry. Impurities can include free peptide, copper salts, and truncated sequences from synthesis. Because the complex is dynamic, sample preparation and mobile-phase conditions can shift the observed species. Reported purity values therefore depend on the analytical method and should be interpreted with that context.
Characterizing GHK-Cu requires methods that distinguish the intact complex from free peptide and unbound copper. UV-visible absorption around 600 nm provides a rapid check for copper coordination, while circular dichroism reports on peptide secondary structure. Mass spectrometry confirms the peptide mass and can detect copper adducts under carefully controlled conditions. Electron paramagnetic resonance is particularly informative for Cu(II) because it reveals the ligand field symmetry. No single technique fully defines the complex, so laboratories combine orthogonal methods.
The peptide was first isolated from human albumin in 1973 by Loren Pickart, who later described its copper-binding behavior. Early work linked the complex to wound healing and tissue remodeling. Plasma levels of GHK decline with age, a pattern that stimulated interest in topical and supplemental applications. Researchers have reported that the tripeptide influences collagen synthesis, antioxidant defense, and inflammatory signaling in cell and animal models. Human clinical evidence remains limited and often relies on small studies.
Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.
==== Investigation of Bruno Pacheco ==== On 16 November 2021, leaked chats showed that then presidential secretary Bruno Pacheco attempted to pressure the SUNAT to favor certain companies and individuals. On 19 November 2021, Bruno Pacheco resigned as presidential secretary due to his role in the Walter Ayala controversy, regarding attempts to irregularly promote military personnel. Pacheco maintained that he was resigning in order to stop the smear campaign against the President. His position was replaced by Carlos Jaico. On 23 November 2021, the Public Prosecutor's Office found $20,000 in cash inside Pacheco's office bathroom in the Governmental Palace. Pacheco claimed that this money came from his savings and the salary he received. On 24 November 2021, Alejandro Aguinaga, a Popular Force parliamentarian and president of the Congressional Oversight Commission called on Prime Minister Mirtha Vásquez to indicate what measures would be taken against Pacheco. In response, the Free Peru parliamentarian Guillermo Bermejo accused the Fujimorist Popular Force of double standards and brought up corruption charges against Alberto Fujimori and Vladimiro Montesinos. Meanwhile, the former prime minister Guido Bellido said "It makes me suspicious that someone goes to work with his 20 thousand dollars," and stated that it would be evaluated and taken into account in Free Peru's stance on the impeachment motion.
{\displaystyle {{\frac {q}{A}}_{min}}=C{{h}_{fg}}{{\rho }_{v}}{{\left[{\frac {\sigma g\left({{\rho }_{L}}-{{\rho }_{v}}\right)}{{\left({{\rho }_{L}}+{{\rho }_{v}}\right)}^{2}}}\right]}^{{}^{1}\!\!\diagup \!\!{}_{4}\;}}}
Valsartan/hydrochlorothiazide, sold under the brand name Diovan HCT among others, is a medication used to treat high blood pressure when valsartan is not sufficient. It is a combination of valsartan, an angiotensin receptor blocker with hydrochlorothiazide, a diuretic. It is taken by mouth. Common side effects include dizziness and headaches. Serious side effects may include allergic reactions, electrolyte abnormalities, and glaucoma. Use in pregnancy is not recommended. The combination was approved for medical use in the United States in 1998. It is available as a generic medication. In 2021, it was the 224th most commonly prescribed medication in the United States, with more than 1 million prescriptions.
=== Protists === Brine pockets harbor a diverse and abundant array of protists that are able to survive in extreme conditions. The most common protists in sea ice are pennate diatoms, which can accumulate in numbers so high that sea ice is visibly discolored brown. Sea ice pennate diatom populations can become very dense, reaching up to 1000 μg of chlorophyll per liter of seawater, compared to a typical maximum of 5 μg/L in the open ocean. Due to their high abundance in sea ice, pennate diatoms can profoundly impact the microecosystem within a brine pocket, such as DMSP production. Although diatoms themselves are not high producers of DMSP overall, because of their high abundance within sea ice, the amount of DMSP produced within sea ice as a cryoprotectant and osmoregulator can be impactful. In addition to pennate diatoms, brine pockets and channels house a variety of flagellates, amoebae, and ciliates. Protist abundance and diversity within a brine pocket/channel is primarily limited to brine pocket/channel structure. Specifically, the size of pores and channels within the ice can limit or encourage the distribution of certain protists and metazoans, with some areas with larger pore sizes having greater abundances of large predatory protists such as ciliates, and other areas with reduced populations of predatory protists due to smaller pore sizes.
Sources: en.wikipedia.org
=== Ribosome inactivation === RTA has rRNA N-glycosylase activity that is responsible for the cleavage of a glycosidic bond within the large rRNA of the 60S subunit of eukaryotic ribosomes. RTA specifically and irreversibly hydrolyses the N-glycosidic bond of the adenine residue at position 4324 (A4324) within the 28S rRNA, but leaves the phosphodiester backbone of the RNA intact. The ricin targets A4324 that is contained in a highly conserved sequence of 12 nucleotides universally found in eukaryotic ribosomes. The sequence, 5'-AGUACGAGAGGA-3', termed the sarcin-ricin loop, is important in binding elongation factors during protein synthesis. The depurination event rapidly and completely inactivates the ribosome, resulting in toxicity from inhibited protein synthesis. A single RTA molecule in the cytosol is capable of depurinating approximately 1500 ribosomes per minute.
In 1994, an EU scientific commission was asked to report on the incidence of mastitis and other disorders in dairy cows and on other aspects of their welfare. The commission's statement, subsequently adopted by the EU, stated that the use of rBST substantially increased health problems with cows, including foot problems, mastitis, and injection site reactions, impinged on the welfare of the animals, and caused reproductive disorders. The report concluded, on the basis of the health and welfare of the animals, rBST should not be used. Health Canada prohibited the sale of rBST in 1999; the external committees found that there was health risk to humans, and the drug present a threat to animal health, and, for this reason, cannot be sold in Canada. Monsanto-sponsored trials reviewed by the FDA asked whether the use of rBST makes cows more susceptible to mastitis. According to the FDA, which used data from eight Monsanto-sponsored trials in its decision in 1993 to approve Monsanto's rBST product, the answer is yes. The data from these eight trials, which involved 487 cows, showed that during the period of rBST treatment, mastitis incidence increased by 76% in primiparous cows and by 50% for multiparous cows. Overall, the increase was 53%. Conversely, however, a study from the University of Georgia on the monitoring post-approval of rBST, showed that there was no statistically significant (P > 0.05) derivation in cases of clinical mastitis in dairy cows treated with rBST.
=== Dynamics === It is important to distinguish between the frequency of de novo gene birth and the number of de novo genes in a given lineage. If de novo gene birth is frequent, it might be expected that genomes would tend to grow in their gene content over time; however, the gene content of genomes is usually relatively stable. This implies that a frequent gene death process must balance de novo gene birth, and indeed, de novo genes are distinguished by their rapid turnover relative to established genes. In support of this notion, recently emerged Drosophila genes are much more likely to be lost, primarily through pseudogenization, with the youngest orphans being lost at the highest rate; this is despite the fact that some Drosophila orphan genes have been shown to rapidly become essential. A similar trend of frequent loss among young gene families was observed in the nematode genus Pristionchus. Similarly, an analysis of five mammalian transcriptomes found that most ORFs in mice were either very old or species specific, implying frequent birth and death of de novo transcripts. A comparable trend could be shown by further analyses of six primate transcriptomes. In wild S. paradoxus populations, de novo ORFs emerge and are lost at similar rates. Nevertheless, there remains a positive correlation between the number of species-specific genes in a genome and the evolutionary distance from its most recent ancestor. A rapid gain and loss of de novo genes was also found on a population level by analyzing nine natural three-spined stickleback populations.
OpenAI co-founder Andrej Karpathy criticized AI agents as being ineffective and promoting AI slop. Issues with multi-agent systems include few coordination protocols between component agents, inconsistent performance, and challenges debugging. In November 2025, Anthropic claimed that a group of hackers sponsored by China attempted a cyberattack against at least 30 organizations by using Claude Code in an agentic workflow, and that several of these infiltrations had succeeded. However, independent cybersecurity researchers questioned the significance of Anthropic's findings. Whittaker argued that the push by Big Tech companies to deploy AI agents risked security vulnerabilities across the Internet.
== Honors and awards == American Heart Association Basic Research Prize (1993) William B. Coley Award for Distinguished Research in Basic and Tumor Immunology (1995) Member of the National Academy of Sciences (1996) Member of the National Academy of Medicine (2023) Fellow of the American Academy of Arts and Sciences (2001) Crafoord Prize in Polyarthritis (2004) Guggenheim Fellowship (2004) Fellow of the American Association for the Advancement of Science (2013) AAI-Life Technologies Meritorious Career Award (now AAI-Thermo Fisher Meritorious Career Award), American Association of Immunologists (2014) Henry M. Stratton Medal, American Society of Hematology (2014) Canada Gairdner International Award (2019) Albert Lasker Award for Basic Medical Research (2022) Robert Koch Prize (2023) Biophysical Society Founders Award (2022) The Protein Society Stein & Moore Award (2025) Fellow of the National Academy of Inventors (2025) Included in Forbes’ 250: America’s Greatest Innovators list (2026) Selected to receive the American Society for Biochemistry and Molecular Biology’s Bert and Natalie Vallee Award in Biomedical Science (2027) He was a Phi Beta Kappa graduate from the University of California, Berkeley.
Sources: en.wikipedia.org
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide coordinates the metal through its histidine imidazole, terminal amino group, and amide nitrogen. It is studied in biochemistry and dermatological research.
Yes, the peptide and its copper complex have been detected in human plasma, saliva, and urine. Endogenous concentrations are low and vary with physiological state. Its natural functions are not fully established.
Copper binding changes the peptide's charge, shape, and reactivity. The complex can participate in redox chemistry and interact with proteins differently than the free peptide. These differences are why studies specify whether they used GHK or GHK-Cu.
Lyophilized material is normally held at about minus twenty degrees Celsius in a sealed, desiccated vial. Dissolved samples are less durable and are prepared fresh. Repeated freeze-thaw cycles are avoided.